Literature DB >> 16792690

Monocyte chemoattractant protein-1 (MCP-1) inhibits the intestinal-like differentiation of monocytes.

T Spoettl1, M Hausmann, M Herlyn, M Gunckel, A Dirmeier, W Falk, H Herfarth, J Schoelmerich, G Rogler.   

Abstract

Monocytes (MO) migrating into normal, non-inflamed intestinal mucosa undergo a specific differentiation resulting in a non-reactive, tolerogenic intestinal macrophage (IMAC). Recently we demonstrated the differentiation of MO into an intestinal-like macrophage (MAC) phenotype in vitro in a three-dimensional cell culture model (multi-cellular spheroid or MCS model). In the mucosa of patients with inflammatory bowel disease (IBD) in addition to normal IMAC, a reactive MAC population as well as increased levels of monocyte chemoattractant protein 1 (MCP-1) is found. The aim of this study was to investigate the influence of MCP-1 on the differentiation of MO into IMAC. MCS were generated from adenovirally transfected HT-29 cells overexpressing MCP-1, macrophage inflammatory protein 3 alpha (MIP-3alpha) or non-transfected controls and co-cultured with freshly elutriated blood MO. After 7 days of co-culture MCS were harvested, and expression of the surface antigens CD33 and CD14 as well as the intracellular MAC marker CD68 was determined by flow-cytometry or immunohistochemistry. MCP-1 and MIP-3alpha expression by HT-29 cells in the MCS was increased by transfection at the time of MCS formation. In contrast to MIP-3alpha, MCP-1 overexpression induced a massive migration of MO into the three-dimensional aggregates. Differentiation of IMAC was disturbed in MCP-1-transfected MCS compared to experiments with non-transfected control aggregates, or the MIP-3alpha-transfected MCS, as indicated by high CD14 expression of MO/IMAC cultured inside the MCP-1-transfected MCS, as shown by immunohistochemistry and FACS analysis. Neutralization of MCP-1 was followed by an almost complete absence of monocyte migration into the MCS. MCP-1 induced migration of MO into three-dimensional spheroids generated from HT-29 cells and inhibited intestinal-like differentiation of blood MO into IMAC. It may be speculated that MCP-1 could play a role in the disturbed IMAC differentiation in IBD mucosa.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16792690      PMCID: PMC1942009          DOI: 10.1111/j.1365-2249.2006.03113.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Intestinal macrophages lack CD14 and CD89 and consequently are down-regulated for LPS- and IgA-mediated activities.

Authors:  P D Smith; L E Smythies; M Mosteller-Barnum; D A Sibley; M W Russell; M Merger; M T Sellers; J M Orenstein; T Shimada; M F Graham; H Kubagawa
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

2.  Hyaluronic acid and chondroitin sulphate A rapidly promote differentiation of immature DC with upregulation of costimulatory and antigen-presenting molecules, and enhancement of NF-kappaB and protein kinase activity.

Authors:  R Yang; Z Yan; F Chen; G K Hansson; R Kiessling
Journal:  Scand J Immunol       Date:  2002-01       Impact factor: 3.487

3.  Subtractive screening reveals up-regulation of NADPH oxidase expression in Crohn's disease intestinal macrophages.

Authors:  M Hausmann; T Spöttl; T Andus; G Rothe; W Falk; J Schölmerich; H Herfarth; G Rogler
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

Review 4.  Chemokines in the inflammatory bowel diseases.

Authors:  R P MacDermott
Journal:  J Clin Immunol       Date:  1999-09       Impact factor: 8.317

5.  Influence of non-enzymatically glycated collagen on monocyte-macrophage differentiation.

Authors:  S S Jacob; P Shastry; P R Sudhakaran
Journal:  Atherosclerosis       Date:  2001-12       Impact factor: 5.162

6.  Monocyte differentiation in intestine-like macrophage phenotype induced by epithelial cells.

Authors:  T Spöttl; M Hausmann; M Kreutz; A Peuker; D Vogl; J Schölmerich; W Falk; R Andreesen; T Andus; H Herfarth; G Rogler
Journal:  J Leukoc Biol       Date:  2001-08       Impact factor: 4.962

7.  Colonic epithelial cells are a major site of macrophage inflammatory protein 3alpha (MIP-3alpha) production in normal colon and inflammatory bowel disease.

Authors:  J H Kwon; S Keates; L Bassani; L F Mayer; A C Keates
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

8.  Physiological role of macrophage inflammatory protein-3 alpha induction during maturation of intestinal macrophages.

Authors:  Martin Hausmann; Frauke Bataille; Tanja Spoettl; Katja Schreiter; Werner Falk; Juergen Schoelmerich; Hans Herfarth; Gerhard Rogler
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

9.  Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation.

Authors:  M Hausmann; S Kiessling; S Mestermann; G Webb; T Spöttl; T Andus; J Schölmerich; H Herfarth; K Ray; W Falk; G Rogler
Journal:  Gastroenterology       Date:  2002-06       Impact factor: 22.682

10.  Monocyte-macrophage differentiation in vitro: modulation by extracellular matrix protein substratum.

Authors:  Shiney Susan Jacob; Padma Shastry; P R Sudhakaran
Journal:  Mol Cell Biochem       Date:  2002-04       Impact factor: 3.396

View more
  24 in total

1.  Spheroid-based drug screen: considerations and practical approach.

Authors:  Juergen Friedrich; Claudia Seidel; Reinhard Ebner; Leoni A Kunz-Schughart
Journal:  Nat Protoc       Date:  2009-02-12       Impact factor: 13.491

2.  3D Tumor Spheroid Models for In Vitro Therapeutic Screening of Nanoparticles.

Authors:  Simonas Daunys; Agnė Janonienė; Indrė Januškevičienė; Miglė Paškevičiūtė; Vilma Petrikaitė
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Inflammatory and Immune Activation in Intestinal Myofibroblasts Is Developmentally Regulated.

Authors:  Sharmila Zawahir; Guanghui Li; Aditi Banerjee; Jessica Shiu; Thomas G Blanchard; Adora C Okogbule-Wonodi
Journal:  J Interferon Cytokine Res       Date:  2015-06-23       Impact factor: 2.607

4.  Proinflammatory chemokines in the intestinal lumen contribute to intestinal dysfunction during endotoxemia.

Authors:  Dennis I Sonnier; Stephanie R Bailey; Rebecca M Schuster; Matthew M Gangidine; Alex B Lentsch; Timothy A Pritts
Journal:  Shock       Date:  2012-01       Impact factor: 3.454

Review 5.  Monocyte chemoattractant protein-1 (MCP-1): an overview.

Authors:  Satish L Deshmane; Sergey Kremlev; Shohreh Amini; Bassel E Sawaya
Journal:  J Interferon Cytokine Res       Date:  2009-06       Impact factor: 2.607

6.  Th2 cytokine-induced alterations in intestinal smooth muscle function depend on alternatively activated macrophages.

Authors:  Aiping Zhao; Joseph F Urban; Robert M Anthony; Rex Sun; Jennifer Stiltz; Nico van Rooijen; Thomas A Wynn; William C Gause; Terez Shea-Donohue
Journal:  Gastroenterology       Date:  2008-04-04       Impact factor: 22.682

7.  Cell senescence abrogates the therapeutic potential of human mesenchymal stem cells in the lethal endotoxemia model.

Authors:  Juan Carlos Sepúlveda; María Tomé; María Eugenia Fernández; Mario Delgado; Judith Campisi; Antonio Bernad; Manuel A González
Journal:  Stem Cells       Date:  2014-07       Impact factor: 6.277

8.  SerpinB2 is critical to Th2 immunity against enteric nematode infection.

Authors:  Aiping Zhao; Zhonghan Yang; Rex Sun; Viktoryia Grinchuk; Sarah Netzel-Arnett; Ian E Anglin; Kathryn Hodge Driesbaugh; Luigi Notari; Jennifer A Bohl; Kathleen B Madden; Joseph F Urban; Toni M Antalis; Terez Shea-Donohue
Journal:  J Immunol       Date:  2013-04-29       Impact factor: 5.422

9.  IFNβ autocrine feedback is required to sustain TLR induced production of MCP-1 in macrophages.

Authors:  Michael J Pattison; Kirsty F MacKenzie; Suzanne E Elcombe; J Simon C Arthur
Journal:  FEBS Lett       Date:  2013-03-28       Impact factor: 4.124

10.  Chemo-enzymatic synthesis and in vitro cytokine profiling of tailor-made oligofructosides.

Authors:  Arne Homann; Malte Timm; Jürgen Seibel
Journal:  BMC Biotechnol       Date:  2012-11-26       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.